Search Results - "Vazquez Estevez, S."

Concurrent chemoradiation for locally advanced stage III non-small cell lung cancer with cisplatin, vinorelbine, and thoracic radiotherapy: a phase II study from the Galician Lung Cancer Group by Costa Rivas, M., Huidobro Vence, G., Fírvida Pérez, J. L., Campos Balea, B., García Gonzalez, J., Lázaro Quintela, M., Caeiro Muñoz, M., Taboada Valladares, B., Castro Gómez, J. E., Vázquez Estevez, S., Afonso Afonso, F. J., Azpitarte Raposeiras, C., Amenedo Gancedo, M., Casal Rubio, J.

“…Purpose The aim of this phase II study was to evaluate the activity and safety of the combination of cisplatin and vinorelbine with thoracic radiotherapy in…”
Get full text

Epidemiological characteristics of a Spanish cohort of patients diagnosed with squamous cell carcinoma of head and neck: distribution of risk factors by tumor location by Seijas-Tamayo, R., Fernández-Mateos, J., Adansa Klain, J. C., Mesía, R., Pastor Borgoñón, M., Pérez-Ruiz, E., Vázquez Fernández, S., Salvador Coloma, C., Rueda Domínguez, A., Taberna, M., Martínez-Trufero, J., Bonfill Abella, T., Vázquez Estévez, S., Pollán, M., del Barco Morillo, E., Cruz-Hernández, J. J.

“…Purpose Head and neck cancer is a highly heterogeneous disease comprising a large number of tumors located in the cervicofacial area. This study aimed to…”
Get full text

Androgen receptor gene status in plasma DNA associates with worse outcome on enzalutamide or abiraterone for castration-resistant prostate cancer: a multi-institution correlative biomarker study by Conteduca, V., Wetterskog, D., Sharabiani, M.T.A., Grande, E., Fernandez-Perez, M.P., Jayaram, A., Salvi, S., Castellano, D., Romanel, A., Lolli, C., Casadio, V., Gurioli, G., Amadori, D., Font, A., Vazquez-Estevez, S., González del Alba, A., Mellado, B., Fernandez-Calvo, O., Méndez-Vidal, M.J., Climent, M.A., Duran, I., Gallardo, E., Rodriguez, A., Santander, C., Sáez, M.I., Puente, J., Gasi Tandefelt, D., Wingate, A., Dearnaley, D., Demichelis, F., De Giorgi, U., Gonzalez-Billalabeitia, E., Attard, G.

“…There is an urgent need to identify biomarkers to guide personalized therapy in castration-resistant prostate cancer (CRPC). We aimed to clinically qualify…”
Get full text

Expression of Notch1 to -4 and their ligands in renal cell carcinoma: a tissue microarray study by Aparicio, L M Antón, Villaamil, V Medina, Gallego, G Aparicio, Caínzos, I Santamarina, Campelo, R García, Rubira, L Valbuena, Estévez, S Vázquez, Mateos, L León, Perez, J L Firvida, Vázquez, M Ramos, Calvo, O Fernández, Bolós, M Victoria

“…Mutations in signalling pathways essential for embryonic development often lead to tumourigenesis, as is also true for Notch. The aim of this study was to…”
Get more information

Phase II study of a fixed dose-rate infusion of gemcitabine associated with uracil/tegafur in advanced carcinoma of the pancreas by Feliu, J., Mel, R., Borrega, P., López Gómez, L., Escudero, P., Dorta, J., Castro, J., Vázquez-Estévez, S. E., Bolaños, M., Espinosa, E., González Barón, M.

“…Background: The objectives of this study were to evaluate the efficacy and toxicity of a fixed dose-rate infusion of gemcitabine associated with uracil/tegafur…”
Get full text

2623 Prospective validation of prognostic classifications in patients (pt) progressing to first-line chemotherapy in metastatic transitional-cell carcinoma (mTCC) by Arija, J.A. Arranz, Vazquez-Estevez, S, Perez-Valderrama, B, del Muro, X. Garcia, Laínez Milagro, N, Sala, N, Fita, M.J. Juan, Noguerón, E, Sáez, M.I, Rey, P. Maroto, Font, A, Díaz, E. Gallardo, Méndez-Vidal, M.J, Criado, M.P. Lopez, Quintela, M. Lázaro, Marin, A. Pinto, del Alba, A. Gonzalez, Caro, R. Luque, Lobera, C. Santander, Martínez, I. Duran

Get full text

Synchronous versus metachronous brain metastasis from testicular germ cell tumors (TGCT): an analysis from the Spanish Germ Cell Cancer Group data base by Girones, R., Aparicio, J., Roure, P., Germa-Lluch, J. R., García del Muro, X., Vazquez-Estevez, S., Saenz, A., Sastre, J., Arranz Arija, J., Gallardo, E., Gonzalez-Billalabeitia, E., Sanchez-Hernandez, A., Terrasa, J., Hernandez, A., Santander, C., Cillan, E., Sagastibelza, N., Almenar-Cubells, D., Lopez Brea, M., Maroto, J. P.

“…Background Brain metastases of testicular germ cell tumor (TGCT) are a rare event. Prognostic is poor and there is not much evidence on optimal management of…”
Get full text

9110 Temozolomide as concomitant treatment to radiotherapy in non-small cell lung cancer patients with brain metastasis: a Galician lung cancer group study by Antonio, G, Mateos, L. León, Perez, J.L. Fírvida, Vazquez Estevez, S, Gómez, E. Castro, Muñoz, M. Caeiro, Balea, B. Campos, Varela Pazos, A, Herranz, U. Anido, Rubio, J. Casal

Get full text

9100 Induction Docetaxel (D) and Cisplatin (C) plus concurrent Thoracic Radiotherapy (TRT) and biweekly D and C for stage III non-small cell lung cancer (NSCLC) – a Galician Lung Cancer Group study by Rubio, J. Casal, Vazquez Estevez, S, Quintela, M. Lázaro, Balea, B. Campos, Herranz, U. Anido, Vence, G. Huidobro, Caamaño, A. Gomez, Muñoz, M. Caeiro, Perez, J.L. Firvida, Gancedo, M. Amenedo

Get full text

A new scenario in metastatic renal cell carcinoma: a SOG-GU consensus by Vázquez Estévez, S., Anido, U., Lázaro, M., Fernández, O., Fernández Núñez, N., de Dios Álvarez, N., Varela, V., Campos Balea, B., Agraso, S., Areses, M. C., Iglesias, L., Blanco, M., Maciá, S., Anton Aparicio, L. M.

“…Background This article describes and compares approved targeted therapies and the newer immunotherapy agents. Materials and methods This article especially…”
Get full text

1793P PPROSTRATEGY: A SOGUG randomized trial of androgen deprivation therapy (ADT) plus docetaxel (dct) +/- nivolumab (nivo) or ipilimumab-nivolumab (ipi-nivo) in high-volume metastatic hormone-sensitive prostate cancer (hvHSPCa) - Safety and toxicity profiles from the pilot phase by Arranz Arija, J.A., Vazquez Estevez, S., Alonso Gordoa, T., Sepúlveda Sánchez, J.M., Perez Valderrama, B., Climent Duran, M.A., Gallardo Diaz, E., Lázaro Quintela, M., Lainez Milagro, N., Domenech Santasusana, M., Gonzalez del Alba Baamonde, M.A., Abad Villar, M.T., Crespo Herrero, G., Alvarez Fernandez, C., Mellado Gonzalez, B., Zambrana Tevar, F.J., Lopez Lopez, C., Perez Ramirez, S., Villa Guzmán, J.C., Piulats Rodriguez, J.M.

Get full text

1783P PROSTRATEGY: A SOGUG randomized trial of androgen deprivation therapy (ADT) plus docetaxel (dct) +/- nivolumab (nivo) or ipilimumab-nivolumab (ipi-nivo) in high-volume metastatic hormone-sensitive prostate cancer (hvHSPCa) - Efficacy results from the pilot phase by Arranz Arija, J.A., Piulats Rodriguez, J.M., Vazquez Estevez, S., Sepúlveda Sánchez, J.M., Alonso Gordoa, T., Perez Valderrama, B., Sala González, N., Climent Duran, M.A., Gallardo Diaz, E., Rodriguez-Vida, A., Caballero Diaz, C., Puente, J., Mendez Vidal, M.J., Parra, E.M.F., Martín, R.C., Virizuela Echaburu, J.A., Gragera, M.B.G., García Sanchez, J., García-Carbonero, I., Carles Galceran, J.

Get full text

55P MOREL: Multicenter observational study on treatment and PD-L1 testing in patients (pts) with newly diagnosed stage IV NSCLC in Spain by Rubio-Viqueira, B., Tarruella, M. Majem, Lazaro, M.E., Estevez, S. Vazquez, Cordoba-Ortega, J.F., Maiques, I. Maestu, Gonzalez, J.J. Garcia, Cordellat, A. Blasco, Valdivia-Bautista, J., Arenas, C. Gonzalez, Torres, J.M. Sanchez

Get full text

6602 POSTER Induction docetaxel and cisplatin followed by bi-weekly docetaxel with concurrent thoracic radiotherapy for stage III non-small cell lung cancer (NSCLC). A phase II study conducted by the Galician Lung Cancer Group (GLCG) by Casal Rubio, J, Vazquez Estevez, S, Lazaro Quintela, M, Campos Balea, B, Grande Ventura, C, Vazquez Tuñas, L, Areses Manrique, K, Firvida Gomez, J.L, Amenedo Gancedo, M, Silva, M.C

Get full text

761P Impact of the combination of durvalumab (MEDI4736) plus olaparib (AZD2281) administered prior to surgery in the molecular profile of resectable urothelial bladder cancer. NEODURVARIB trial by Rodriguez-Moreno, J.F., de Velasco, G., Alvarez-Fernandez, C., Collado, R., Fernandez-Rodriguez, R., Estevez, S. Vazquez, Virizuela Echaburu, J.A., Gajate Borau, P., Font, A., Lainez, N., Sevillano Fernandez, E., Ruiz, S., Beltran, L., Rodriguez-Antona, C., Berraondo, P., Garcia-Donas, J.

Get full text

639P 223Ra in asymptomatic patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) who progressed to first-line abiraterone acetate or enzalutamide by Carles, J., Alonso, T., Mellado Gonzalez, B., Mendez Vidal, M.J., Vazquez Estevez, S., González del Alba, A., Piulats, J.M., Borrega García, P., Gallardo, E., Morales Barrera, R., Paredes, P., Reig, O., Garcías de España, C., Collado, R., Bonfill, T., Suarez, C., Malfettone, A., Garde, J.

Get full text

759P Towards personalized medicine in MIBC: Immunohistochemistry-based taxonomical classification and outcome in patients treated with adjuvant chemotherapy by Gauna, D. Castellano, Grande, E., Duran, M.A. Climent, Lainez, N., Duran, I., Carrato, C., Lobato, T., Andrada, E., Gonzalez, R. Gonzalez, Astudillo, L., Estevez, S. Vazquez, Gonzalez, B. Mellado, Carbonero, I. García, Quintela, M. Lázaro, Saez, M., Billalabeitia, E. Gonzalez, Arnau, M. Guix, Font, A., Malats, N., Real, F.

Get full text

954P - SPAZO2 (SOGUG): Outcomes and prognostic significance of IMDC intermediate prognosis subclassification in metastatic renal cell carcinoma (mRCC) in patients treated with 1st-line pazopanib (1stPz) by Valderrama, B.P., Perez Ramirez, S., Rodriguez-Vida, A., González del Alba, A., Mendez Vidal, M.J., Vazquez Estevez, S., Martinez Ortega, E., Virizuela, J.A., Fernández Calvo, O., Hernández Jorge, A., Vazquez Mazon, F.J., Gonzalez Gragera, M.B., Campayo, M., Etxaniz Ulazia, O., Almagro Casado, E., Sereno Moyano, M., Abad Villar, M.T., Suarez Rodriguez, C., Gallardo Diaz, E., Arranz Arija, J.A.

“…IMDC classifies patients (pt) with mRCC in favorable, intermediate or poor-risk (FR, IR, PR). IR pt having 1 vs 2 unfavorable factors (IR1 vs IR2) treated with…”
Get full text

954PSPAZO2 (SOGUG): Outcomes and prognostic significance of IMDC intermediate prognosis subclassification in metastatic renal cell carcinoma (mRCC) in patients treated with 1st-line pazopanib (1stPz) by Valderrama, B P, Perez Ramirez, S, Rodriguez-Vida, A, González del Alba, A, Mendez Vidal, M J, Vazquez Estevez, S, Martinez Ortega, E, Virizuela, J A, Fernández Calvo, O, Hernández Jorge, A, Vazquez Mazon, F J, Gonzalez Gragera, M B, Campayo, M, Etxaniz Ulazia, O, Almagro Casado, E, Sereno Moyano, M, Abad Villar, M T, Suarez Rodriguez, C, Gallardo Diaz, E, Arranz Arija, J A

“…Abstract Background IMDC classifies patients (pt) with mRCC in favorable, intermediate or poor-risk (FR, IR, PR). IR pt having 1 vs 2 unfavorable factors (IR1…”
Get full text

1461P - NORA trial (GECP 15/02): Updated results of the Spanish Lung Cancer Group (SLCG) phase II trial of concurrent chemo-radiotherapy (CT-RT) with cisplatin (P) plus metronomic oral vinorelbine (mOV) for unresectable locally advanced non-small cell lung cancer (LA-NSCLC) by Guirado, M., Majem, M., Massuti Sureda, B., de las Penas Bataller, R., Ortega Granados, A.L., Isla Casado, M.D., Domine Gomez, M., Marse Fabregat, R., Sala, M.A., Paredes Lario, A., Moran Bueno, M.T., Vazquez Estevez, S., Coves Sarto, J., Gonzalez-Larriba, J.L., Sanchez Torres, J.M., Vicente, D., Farre Bernado, N., Fernandez-Fornos, L., Varcarcel, F., Provencio, M.

“…CT-RT is the standard treatment for unresectable LA-NSCLC. P plus vinorelbine is widely used. Metronomic CT is a frequent administration of low doses of CT…”
Get full text